UNSPSC 51373477: Hydrocodone/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373477 Hydrocodone/pseudoephedrine is a Commodity code that captures state and local procurement of controlled and over-the-counter pharmaceuticals through both direct purchase and cooperative purchasing vehicles. Recent activity shows demand for naloxone kits, safe drug deactivation systems, and generic multi-source pharmaceuticals distributed through authorized wholesale channels. The issuing bodies include county health departments (Seminole County, Florida) and multistate cooperative purchasing alliances administering pharmaceutical contracts on behalf of participating state and local government facilities. Vendors must comply with Drug Supply Chain Security Act (DSCSA) requirements, current Good Manufacturing Practices (cGMP) certification, FDA compliance, and when FEMA funding is involved, additional federal environmental regulations. Contracts typically run two years with renewal options, require comprehensive insurance including workers' compensation and commercial general liability, and in cooperative settings impose administrative fees (ranging from 3 percent to performance penalties of $200–$1,500 per violation).

Procurement activity centers on Minnesota and Florida, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serving participating state and local facilities across multiple states including Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2026. MMCAP issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co.), with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Pricing evaluation in the MMCAP RFP weights price competitiveness at 75 percent, with fixed pricing, administrative compliance, EDI capability, and administrative fee agreement each weighted at 5–10 percent.